Skip to main content
Signal8

GSK plc (GSK) Form 6-K — Nov 18, 2026

$GSKForm 6-KFiled Nov 18, 2026, 7:06 AM ET0001654954-26-009959Original filing

The FDA granted accelerated approval to GSK's Nelkarmi (neladalkib) for adults with previously-treated advanced ALK-positive non-small cell lung cancer, ahead of its original 27 November 2026 target action date. Approval was based on the phase I/II ALKOVE-1 trial, which showed an overall response rate of 49% in patients with only one prior ALK TKI (alectinib) and 32% in heavily pretreated patients, with durable responses and meaningful intracranial activity in CNS metastases.

Key figures

Original fda action date
2026-11-27
Alkove1 enrolled patients
700
Intracranial orr multi tki
26%
Orr alectinib prior cohort
49%
Orr two or more tki cohort
32%
Intracranial orr alectinib prior
55%

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.